Stropeg 6 mg Solution for Injection
PDF Leaflet Revision Date: 13 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
To reduce duration and incidence of neutropenia in patients undergoing cytotoxic chemotherapy.
Dosage (summary)
One 6 mg dose subcutaneously, 24 hours post-chemotherapy.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- Cytotoxic chemotherapy
- Lithium
Contraindications
- Hypersensitivity to pegfilgrastim or E. coli proteins
Common side effects
- Bone pain
- Nausea
- Headache
- Injection site pain
Counselling Points
- Monitor for allergic reactions
- Report any signs of splenic rupture
- Avoid mixing with other medications
Serious warnings
- Risk of splenic rupture
- Capillary leak syndrome
- Pulmonary adverse events
Important Disclaimer
The Stropeg 6 mg Solution for Injection professional information leaflet below is the property of Kahma Biotech and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
